More patients in England with chronic obstructive pulmonary disease (COPD) could soon be able to access rehabilitation programmes, after cost-effectiveness watchdog NICE b
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.